Welcome to Dividend.com
Please help us personalize your experience.
Select the one that best describes you

iShares U.S. Pharmaceuticals ETF

etf
IHE
Dividend policy
Active
Price as of:
$166.44 -2.98 0%
primary theme
Health Care Sector Equity
IHE (ETF)

iShares U.S. Pharmaceuticals ETF

Dividend policy
Active
Price as of:
$166.44 -2.98 0%
primary theme
Health Care Sector Equity
IHE (ETF)
iShares U.S. Pharmaceuticals ETF
Dividend policy
Active
Price as of:
$166.44 -2.98 0%
primary theme
Health Care Sector Equity

IHE - Snapshot

Vitals

  • YTD Return 3.6%
  • 3 Yr Annualized Return 2.8%
  • 5 Yr Annualized Return 3.5%
  • Net Assets $351 M
  • Holdings in Top 10 75.8%

52 WEEK LOW AND HIGH

$169.42
$117.05
$172.13

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.42%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 40.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) N/A
  • IRA N/A

Fund Classification

  • Primary Theme Health Care Sector Equity
  • Fund Type Exchange Traded Fund
  • Investment Style Health

Compare IHE to Popular Health Care Sector Equity Funds and ETFs

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings & Recommendations*

$218.69

-1.29%

$48.66 B

11.11%

$24.60

blocked
blocked
blocked

5.03%

0.32%

$106.21

-1.59%

$23.72 B

1.43%

$1.54

blocked
blocked
blocked

4.41%

0.13%

$95.95

-1.36%

$15.31 B

5.17%

$5.03

blocked
blocked
blocked

17.83%

0.76%

$103.61

-1.58%

$13.24 B

1.72%

$1.81

blocked
blocked
blocked

7.98%

0.10%

$207.09

-1.66%

$13.24 B

1.72%

$3.62

blocked
blocked
blocked

8.06%

0.10%

IHE - Profile

Distributions

  • YTD Total Return 3.9%
  • 3 Yr Annualized Total Return 2.8%
  • 5 Yr Annualized Total Return 3.5%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 1.45%
DIVIDENDS
  • Dividend Yield 1.3%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    iShares U.S. Pharmaceuticals ETF
  • Fund Family Name
    iShares
  • Inception Date
    May 01, 2006
  • Shares Outstanding
    2150000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Greg Savage

Fund Description

The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.


IHE - Performance

Return Ranking - Trailing

Period IHE Return Category Return Low Category Return High Rank in Category (%)
YTD 3.6% -7.5% 112.9% 85.80%
1 Yr 18.5% 8.3% 128.7% 91.93%
3 Yr 2.8%* 0.1% 38.7% 96.50%
5 Yr 3.5%* 0.4% 30.0% 97.84%
10 Yr 11.9%* 8.9% 20.1% 91.06%

* Annualized

Return Ranking - Calendar

Period IHE Return Category Return Low Category Return High Rank in Category (%)
2019 13.8% 3.8% 63.8% 88.97%
2018 -8.8% -49.7% 21.5% 63.50%
2017 9.2% -59.8% 54.4% 81.48%
2016 -12.5% -36.6% 11.6% 34.11%
2015 6.8% -62.4% 27.9% 12.30%

Total Return Ranking - Trailing

Period IHE Return Category Return Low Category Return High Rank in Category (%)
YTD 3.9% -7.5% 118.6% 85.80%
1 Yr 18.5% 2.7% 128.7% 88.20%
3 Yr 2.8%* 0.1% 38.7% 95.80%
5 Yr 3.5%* 0.4% 30.0% 97.12%
10 Yr 11.9%* 8.9% 20.1% 90.24%

* Annualized

Total Return Ranking - Calendar

Period IHE Return Category Return Low Category Return High Rank in Category (%)
2019 13.8% 3.8% 63.8% 88.97%
2018 -8.8% -25.3% 22.2% 66.42%
2017 9.2% -10.8% 54.4% 91.11%
2016 -12.5% -36.6% 11.6% 50.39%
2015 6.8% -16.6% 27.9% 41.80%

IHE - Holdings

Concentration Analysis

IHE Category Low Category High IHE % Rank
Net Assets 351 M 2.6 M 48.7 B 57.80%
Number of Holdings 51 26 431 84.97%
Net Assets in Top 10 266 M 670 K 18.8 B 53.76%
Weighting of Top 10 75.80% 13.2% 76.3% 1.16%

Top 10 Holdings

  1. Johnson & Johnson 22.32%
  2. Merck & Co Inc 19.07%
  3. Horizon Therapeutics PLC 6.38%
  4. Horizon Therapeutics PLC 6.38%
  5. Horizon Therapeutics PLC 6.38%
  6. Horizon Therapeutics PLC 6.38%
  7. Horizon Therapeutics PLC 6.38%
  8. Horizon Therapeutics PLC 6.38%
  9. Horizon Therapeutics PLC 6.38%
  10. Horizon Therapeutics PLC 6.38%

Asset Allocation

Weighting Return Low Return High IHE % Rank
Stocks
99.77% 61.47% 106.08% 24.86%
Cash
0.23% -6.08% 32.46% 72.83%
Preferred Stocks
0.00% 0.00% 6.63% 41.62%
Other
0.00% -3.06% 6.07% 45.66%
Convertible Bonds
0.00% 0.00% 0.03% 30.64%
Bonds
0.00% 0.00% 16.11% 32.37%

Stock Sector Breakdown

Weighting Return Low Return High IHE % Rank
Healthcare
100.00% 61.81% 100.00% 11.56%
Utilities
0.00% 0.00% 0.00% 29.48%
Technology
0.00% 0.00% 20.28% 41.04%
Real Estate
0.00% 0.00% 6.03% 35.26%
Industrials
0.00% 0.00% 6.39% 35.84%
Financial Services
0.00% 0.00% 2.72% 54.91%
Energy
0.00% 0.00% 0.00% 29.48%
Communication Services
0.00% 0.00% 3.21% 31.79%
Consumer Defense
0.00% 0.00% 34.31% 35.84%
Consumer Cyclical
0.00% 0.00% 1.21% 35.26%
Basic Materials
0.00% 0.00% 2.61% 49.13%

Stock Geographic Breakdown

Weighting Return Low Return High IHE % Rank
US
96.67% 47.91% 106.08% 12.72%
Non US
3.10% 0.00% 43.87% 85.55%

IHE - Expenses

Operational Fees

IHE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.42% 0.08% 25.14% 89.16%
Management Fee 0.42% 0.00% 1.25% 12.14%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.40% N/A

Sales Fees

IHE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

IHE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

IHE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 40.00% 0.70% 252.00% 58.54%

IHE - Distributions

Dividend Yield Analysis

IHE Category Low Category High IHE % Rank
Dividend Yield 1.28% 0.00% 3.15% 4.05%

Dividend Distribution Analysis

IHE Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annually Semi-Annually Annually

Net Income Ratio Analysis

IHE Category Low Category High IHE % Rank
Net Income Ratio 1.45% -2.53% 2.53% 4.79%

Capital Gain Distribution Analysis

IHE Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

IHE - Fund Manager Analysis

Managers

Greg Savage


Start Date

Tenure

Tenure Rank

Jan 01, 2008

12.76

12.8%

Greg Savage, Managing Director; has been associated with BlackRock Fund Advisors since 2009. Mr. Savage has been a senior portfolio manager for BFA and BTC since 2009. Prior to his employment with BFA and BTC, Mr. Savage was a senior portfolio manager from 2006 to 2009 for BGFA and BGI and a portfolio manager from 2001 to 2006 for BGFA and BGI.

Jennifer Hsui


Start Date

Tenure

Tenure Rank

Sep 01, 2012

8.08

8.1%

Jennifer Hsui has been employed by BlackRock Fund Advisors as a senior portfolio manager since 2007. Prior to that, Ms. Hsui was a portfolio manager from 2006 to 2007 for BGFA. She was a research analyst for RBC Capital Markets from 2003 to 2006.

Alan Mason


Start Date

Tenure

Tenure Rank

Apr 15, 2016

4.46

4.5%

Alan Mason is a Managing Director of BlackRock Advisors, LLC since 2009. Previously, Mr. Mason was a Managing Director of Barclays Global Investors from 2008 to 2009 and a Principal from 1996 to 2008.

Amy Whitelaw


Start Date

Tenure

Tenure Rank

Aug 01, 2018

2.17

2.2%

Amy Whitelaw is Managing Director of BlackRock, Inc. since 2013 and was Director of the firm from 2009 to 2012. Ms. Whitelaw's service with the firm dates back to 1998, including her years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Ms. Whitelaw served as Principal of BGI from 2000 to 2009. Previously Ms. Whitelaw worked in the Transition Services group as a transition manager and strategist, and was also an international equity trader on BGI’s trading desk.

Rachel Aguirre


Start Date

Tenure

Tenure Rank

Aug 01, 2018

2.17

2.2%

Rachel Aguirre is a Managing Director of BlackRock, Inc. since 2018. Rachel Aguirre has been with BlackRock since 2006, including her years with Barclays Global Investors (“BGI”), which merged with BlackRock in 2009.Ms. Aguirre was previously a Director of BlackRock, Inc. from 2012 to 2017, Vice President of BlackRock, Inc. from 2009 to 2011 and Principal and Portfolio Manager of Barclays Global Investors from 2005 to 2009.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.08 23.06 7.22 20.43